

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 16, No. 22

December 1st, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- CY2018 PFS, HOPPS, & QPP
- IV fluid shortage update
- *Medicare Reimbursement for Oncology*
- *Best of SABCS San Francisco*
- *Multidisciplinary Management of Cancers*

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members.

The next regular *ANCO FAX News* will be published on December 15th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The ANCO FAX News has information for every member of your practice or organization. Pass it along!

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The *Association of Northern California Oncologists* (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge.

The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

The Senate tax reform legislation would trigger sequestration and threatened cuts to Medicare of approximately \$25B. ANCO and ASCO urge members to urge their *Senators* to act to avoid Medicare cuts in the tax reform legislation via cqrcengage.com/asco/?3.

The *United States Federal Drug Administration's Division of Drug Information* is hosting a complimentary webinar entitled *Overview of the Regulatory Framework and the Development and Approval of Biosimilar Produces in the U.S.* The webinar will define the difference between biosimilar and interchangeable products, provide an overview of the regulatory framework for biosimilar products, and explain the general requirements of the approval pathway for biosimilars. Learn more and register at collaborationcqpul.fda.gov/content/connect/c1/7/en/events/event/shared/94630851/event_registration.html?sco-id=127063551&_charset_=utf-8.

CMS released the CY2018 *Physician Fee Schedule (PFS) and Outpatient Prospective Payment System (OPPS) final rules on November 2nd*. Listen/view a recording of ACCC's webcast entitled *2018 OPPS/PFS Final Rules: What You Need to Know* at <https://attendee.gotowebinar.com/recording/viewRecording/3246328258799617539/4538641450016057608/execdir@anco-online.org>; Bobbi Buell's analysis of the final rules is available at www.anco-online.org/BBMPFS2018Analysis.pdf.

ASCO and seven other medical societies sent a letter to the leaders of the *Senate Finance Committee, House Energy and Commerce Committee, and House Ways and Means Committee* asking lawmakers to take action this year to remove Part B drug payments from the Merit-based Incentive Payment System (MIPS) score adjustment. The recently released CMS CY2018 *Physician Fee Schedule* makes Part B drug reimbursement subject to MIPS adjustments. Read the letter at www.asco.org/sites/new-www.asco.org/files/content-files/blog-release/pdf/2017-Joint-MIPS-PartB-Letter.pdf. In addition, ASCO is urging the *Administration* to develop multiple oncology-specific alternative payment models (APMs) that will enable oncologists to select the optimal approach for their patients and allow their practices to successfully transition to a value-based payment environment. Specifically, ASCO submitted a proposal for a new voluntary cancer-focused APM that would provide resources to better support the full range of services needed for oncology care planning and management, reduce unwarranted variation and cost by promoting evidence-based care, and organize reimbursement so that it works for a variety of care settings. Read ASCO's proposal at www.asco.org/sites/new-www.asco.org/files/content-files/blog-release/pdf/2017-ASCO-CMMI-CoverLetter.pdf.

The *Medicare Quality Payment Program (QPP)*, established by the *Medicare Access and CHIP Reauthorization Act (MACRA)*, began on January 1st. This year is a transition year meaning you can "pick your pace" when implementing QPP in your practice. CMS has posted new resources to the QPP website to help clinicians successfully participate in the first year of the QPP. The new resources focus on support for small practices and alternative payment models (APMs). Visit qpp.cms.gov for more information. In addition, CMS is now accepting hardship exceptions from the QPP for the 2017 reporting year based on

insufficient internet connectivity, extreme and uncontrollable circumstances, and lack of control over the availability of certified EHR technology. Learn more at qpp.cms.gov/about/hardship-exception.

ASCO's Quality Oncology Practice Initiative (QOPI) Qualified Clinical Data Registry (QCDR) is available for CMS MIPS reporting. By using the QOPI QCDR for MIPS reporting, practices will be able to report in 2017 and 2018 to avoid cuts to Medicare reimbursements in 2019 and 2020. Express your interest in participating in the QOPI QCDR by e-mailing qopi@asoc.org. Practices will be contacted regarding the necessary steps to begin their on-boarding process. For more information, please visit www.instituteforquality.org/qopi/about/quality-reporting or attend ASCO's 30-minute QOPI Reporting Registry webinar (www.instituteforquality.org/qopi/about/quality-reporting?).

ASCO's series of webinars to guide oncology practices to successful quality reporting are available at www.asco.org/macra > MACRA Webinar Series. **ASCO has developed a MACRA decision tree tool to help oncology practices find precise information on their QPP participation status** at www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-practice-tools/determine-status. For more information and access to ASCO's revamped QPP/MACRA toolkit, educational materials, and resources, go to www.asco.org/macra. ASH's updated MACRA webpage is at www.hematology.org/Clinicians/7427.aspx. **ASH members can now sign up to report data for the Medicare MIPS through Healthmonix's MIPSPRO, a 2017 Qualified MIPS Registry.** Learn more at healthmonix.com/mips-pro/.

The American Medical Association (AMA) has produced a new short video entitled *One Patient, One Measure, No Penalty: How to avoid a Medicare payment penalty with basic reporting.*

The video and other AMA resources are available at www.ama-assn.org/qpp-reporting. **CMA's Center for Economic Services (CES) has published an update to its MACRA preparation checklist** entitled *MACRA: What Should I Do Now to Prepare?* available at www.cmanet.org/macra. **Physicians in practices with 15 or fewer can receive free assistance to prepare and participate in the QPP through the California Health Information Partnership & Services Organization (CalHIPSO).** Contact CalHIPSO at www.hsag.com/calhipso (or see their announcement at www.anco-online.org/CalHIPSO&QPP.pdf).

ASCO has met with the FDA and other stakeholders to discuss recent drug shortages and some temporary solutions to help alleviate the situation. In response, the FDA issued a statement addressing the shortages and outlining solutions (at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585720.htm). *Baxter Healthcare Corporation* in conjunction with FDA has initiated temporary importation of some intravenous drug products from its facilities in other countries (e.g., Canada). Visit FDA's dedicated webpage at www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Chloride%200.9per%20Injection%20Bags&st=c for the latest information; see the Dear Healthcare Professional letter at www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM581644.pdf. *The American Society of Health-System Pharmacists* and the *University of Utah Drug Information Service* have developed a document with suggestions for management and conservation of small-volume parenteral solutions (SVPs) at www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM582461.pdf. In addition, **ASCO signed onto a joint letter to the House Energy and Commerce Subcommittee on Oversight and Investigations asking Congress to raise awareness about the persistent shortages of critical medications and resulting public health crises.**

Read the letter at www.ashp.org/-/media/assets/advocacy-issues/docs/GRD-Letter-to-EC-on-SVP-Shortages.

CMA, MOASC, and State Legislative & Regulatory Issues

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe.

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) *Medicare Administrative Contractor* (MAC). Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—Medicare Clinical Laboratory Fee Schedule: Final CY2018 Payment Rates; 2017 Medicare FFS Improper Payment Rate Below 10 Percent for First Time Since 2013 *Claims, Pricers, and Codes*—Billing for Stem Cell Transplants-Reminder *Publications*—Medicare Fraud & Abuse Poster-New; Medicare Fraud & Abuse: Prevention, Detection, and Reporting Booklet-Revised; Quality Payment Program 2017: MIPS ACI Performance Category Web-Based Training Course-New
- MSP Payment Calculator Now Offers Enhanced Details
- MolDX: Bladder Tumor Marker FISH Billing and Coding Guidelines-R2

- DecisionDx-UM Billing Guidelines Article Retirement-Effective September 22, 2017
- MolDX: AlloSure Donor-Derived Cell-Free DNA Test Final LCD-Effective December 11, 2017
- HCPCS Codes Used for Home Health Consolidated Billing Enforcement-Annual Update
- Claim Status Category Codes and Claim Status Codes Update
- Therapy Cap Values for CY2018
- 2018 Medicare Physician Fee Schedule Now Available
- PET Radiopharmaceutical/Tracer Unclassified Codes
- 2018 Medicare Parts A & B Premiums and Deductibles Announced
- MolDX: Molecular RBC Phenotyping LCD-R2
- Special Histochemical Stains and Immunohistochemical Stains LCD-R3
- MolDX: Circulating Tumor Cell Marker Assays-R2
- Therapy Code List-2018 Annual Update CR10303
- Laboratory NCD Edit Software for January 2018-Revised CR10309

Forthcoming *Noridian/JEMAC* meetings/webinars/workshops include:

- Preventive and Screening Services Webinar (December 6)
- Recoupment Timeline and Payment Options Webinar (December 7)
- Medicare Provider Enrollment Webinar (December 12)
- Modifier 59, NCCI and MUE Webinar (December 13)

- Understanding National and Local Coverage Determinations Webinar (December 13)
- Telehealth Services Webinar (December 14)

Visit med.noridianmedicare.com/web/job/education/training-events for more information and to register.

CMS has published a MLN Matters article entitled *Medicare Fee-for-Service (FFS) Response to the 2017 California Wildfires* at www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/SE17035.pdf. CMS has a webpage dedicated to the 2017 California wildfires at www.cms.gov/About-CMS/Agency-Information/Emergency/Wildfires.html.

DHCS/MediCal has detailed the requirements of MediCal plans to provide palliative care services to their beneficiaries in accordance with SB1004 (2014). DHCS/MediCal will implement the palliative care program through managed care and fee-for-service providers beginning on January 1st. Learn more about SB1004 at coalitionccc.org/public-policy/sb1004; read the DHCS all-plan letter at www.dhcs.ca.gov/formsandpubs/Documents/MMCDAPLsandPolicyLetters/APL2017/APL17-015.pdf.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

ANCO's Medicare Reimbursement for Oncology 2017

ANCO will host its annual *Medicare* update programs entitled *Medicare Reimbursement for Oncology in 2018* on January 3rd in San José and January 4th in Sacramento. Roberta Buell, M.B.A., *onPoint Oncology*, will provide the latest information impacting Medicare's reimbursement for oncology in 2018 as well as a *Revenue Cycle*

State of the State with northern California data on denial rates, days to pay, and days to file. The latter presentation will be a unique opportunity to get benchmarks that you can use for billing and appeals at your practice. Download the meeting announcement at www.anco-online.org/MedicareUpdate2018.pdf.

SAVE THE DATE Best of SABCS San Francisco

ANCO, in association with the Organizing Committee of the San Antonio Breast Cancer Symposium and Encore Medical Education, is hosting the *Best of San Antonio Breast Cancer Symposium San Francisco (Best of SABCS San Francisco)* at *The Claremont Hotel* on **Saturday morning, January 27th**. This program is an enhancement of ANCO's traditional *SABCS Highlights*. Hope S. Rugo, M.D., *UC San Francisco*, is the *Regional Director* for *Best of SABCS San Francisco*. The final program agenda with talk titles and presenters for the *Best of SABCS San Francisco* will be finalized soon.

18th Multidisciplinary Management of Cancers: A Case-based Approach

The *18th Multidisciplinary Management of Cancers: A Case-based Approach* returns to the *Silverado Resort and Spa* in Napa on March 16-18th. The meeting is sponsored by the *Association of Northern California Oncologists, Stanford Cancer Institute, UC Davis Comprehensive Cancer Center, and the UCSF Helen Diller Family Comprehensive Cancer Center*. Go to www.multicancers.org for more information including registration and housing.

Additional Education Meetings

December 14th
Update on Chronic Lymphocytic Leukemia (CLL)
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

December 20th
Update on Clinical Trials & Triple Negative Breast Cancer (Part III of Living with Triple Negative Breast Cancer)

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

January 9th

Medical Update on Ovarian Cancer

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

January 11th

Update on Glioblastoma

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

January 12-13th

2018 Highlights of ASH

ASH

San Francisco

(www.hematology.org/Highlights/)

January 13th

Evolving Treatment Options in Lung Cancer

(with David Gandara, M.D., Matthew Gubens, M.D., Jonathan Riess, M.D., & Helen Shih, N.P.)

MedPro Master Lecture Series

San Francisco

(www.cvent.com/d/ptqlwn)

January 18-20th

Gastrointestinal Cancers Symposium

ASCO

San Francisco

(www.gicasym.org)

January 23rd

Update on Lymphoma from the 2017 ASH Annual Meeting

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

January 25-27th

Clinical Immuno-Oncology Symposium

ASCO-SITC

San Francisco

(www.immunosym.org)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors meeting is scheduled for December 12th**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

ASCO seeks applications for volunteers at its ASCO Volunteer Portal (<https://volunteer.asco.org/?>). Your application will be used for all upcoming Volunteer Corps opportunities and 2018 committee consideration. Apply by January 31st for 2018 committee consideration.

The ASCO Nominating Committee has selected 16 distinguished ASCO members as candidates for open leadership positions within the Society. Detailed information on candidates for open positions, including a community oncology seat, is now available at www.asco.org/about-asco/asco-overview/asco-election?. Eligible ASCO members may vote through December 4th.

A current *Directory of Members* is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

Come and join the *Permanente* community for the very first ***Kaiser Permanente National Oncology Symposium*** at the *San Francisco Marriot Marquis Hotel* on April 27-28th. For updates, please visit www.kpsymposia.com

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Marin Cancer Care*, *Pacific Cancer Care*, and *Palo Alto Medical Foundation* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

AbbVie • *Agendia* • *Agios Pharmaceuticals*
Alexion Pharmaceuticals
AMGEN • *ARIAD Pharmaceuticals*
Astellas Oncology • *AstraZeneca*
Bayer Healthcare Pharmaceuticals
bioTheranostics
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • *Clovis Oncology* • *Daiichi Sankyo*
Eisai • *EMD Serono* • *Exelixis*
Foundation Medicine • *Genentech BioOncology*
Genomic Health • *Gilead Sciences*
Guardant Health • *Helsinn Oncology*
Heron Therapeutics • *Incyte*
Janssen Oncology • *Jazz Pharmaceuticals*
Kite Pharmaceuticals • *Lilly Oncology* • *Merck*
nanoString • *Novartis Oncology*
Oncology Supply/ION • *Pfizer Oncology*
Pfizer US Biosimilars • *Pharmacyclics*
Puma Biotechnology • *Sandoz Biopharmaceuticals*
Sanofi Genzyme • *Seattle Genetics*
Taiho Oncology • *Takeda Oncology*
TerSera Therapeutics • *Tesaro*
TEVA Oncology

We especially wish to thank and welcome *Agendia*, *Agios Pharmaceuticals*, *bioTheranostics*, *EMD Serono*, *Kite Pharmaceuticals*, *Pfizer US Biosimilars*, *Puma Biotechnology*, and *TerSera Therapeutics* as new Corporate Members for 2017. *Dendreon*, *Genoptix Medical Laboratory*, *GenPath Oncology*, *Infinity Pharmaceuticals*, *Ipsen Biopharmaceuticals*, *Medivation*, *Merrimack Pharmaceuticals*, and *Prometheus Laboratories* did not renew their memberships for 2017. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

Heron Therapeutics informs ANCO that CMS has assigned HCPCS code J1627 to **Sustol**. In addition, the *United States Food and Drug Administration* has approved **Cinvanti** for the

prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).

Pfizer Oncology informs ANCO that the *United States Food and Drug Administration* has approved Sutent for adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

Pfizer Oncology has implemented emergency relief protocols at *Pfizer RxPathways* to ensure that patients impacted by the northern California wildfires have continued access to their *Pfizer* medicines. If a medicine provided through a *Pfizer* patient assistance program has been destroyed or lost, or patients who are enrolled are unable to reach their doctors' offices and need their medicine shipped to an alternate location, *Pfizer* can arrange for early refills and/or new shipping addresses. If new patients urgently need a *Pfizer* medicine but have been displaced and are unable to access income documentation and other paperwork needed for enrollment into the program, *Pfizer* is able to waive these requirements so that patients can receive their medication as quickly as possible. Facilities that participate in *Pfizer's* bulk replenishment Institutional Patient Assistance Program can request early replenishment of the *Pfizer* medicines covered or request additional inventory to meet increased demand. For help with *Pfizer's* oncology medicines, call *Pfizer Oncology Together* directly at (877) 744-5675; for help with other *Pfizer* medicines, call *Pfizer RxPathways* at (844) 989-PATH (7284).

Clinical Trial News

Stanford Cancer Center brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- BMT302: A Phase 2 Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic hematopoietic Cell Transplantation for Acute Leukemia [NCT03267186]. Principal Investigator: Andrew Rezvani, MD; Contact: Physician Referrals, (650) 723-0822.
- BMT319: A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients [NCT02927067]. Principal Investigator: Janice (Wes) Brown, MD; Contact: Isabelle Nguyen, (650) 723-7362; itnguyen@stanford.edu.
- ECOG-ACRIN-S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With at Least 1cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy [NCT02954874]. Principal Investigator: Melinda Telli, MD; Contact: Caitlin Plahn, (650) 723-3046; cplahn@stanford.edu.
- BRS0070: A Phase 1B Dose-Escalation Trial of Human Anti-4-1BB Agonistic Antibody PF-05082566 in Combination with Adotrastuzumab-Emtansine or Trastuzumab in Patients With HER2-Positive Advanced Breast Cancer. Principal Investigator: George Sledge, MD; Contact: Oshra Sedan, (650) 723-0628; oseedan@stanford.edu.
- VAR0152: A Phase ½ Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Advanced Solid Tumors. Principal Investigator: Shivaani Kummur, MD; Contact: Ferial Buchholz, (650) 721-4090; ferielbu@stanford.edu.
- VAR0154: A Phase ½ Study of the TRK Inhibitor LOXO-195 in Adult Subjects with NTRK Fusion (Previously Treated) or Non-Fusion NTRK Altered Cancers [NCT03215511]. Principal Investigator: Shivaani Kummur, MD; Contact: Jee Min Lee, (650) 721-4084; jeelee@stanford.edu.
- ML28897/PRO 02; Version 2: My Pathway: An Open-label Phase IIa Study Evaluating Trastuzumab + Pertuzumanb, Erlotinib, Vemurafenib + Cobimetinib, Vismodegib, Atezolizumab, or Alectinib in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents [NCT02091141]. Principal Investigator: James Ford, MD; Contact: Kevin Morrison, (650) 725-5459; kmmorris@stanford.edu.
- GYNEND0001: Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117,

Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer [NCT02725268]. Principal Investigator: Oliver Dorigo, MD; Contact: Alma Gonzalez, (650) 498-0624; alma.gonzalez@stanford.edu.

- RENAL0037: A Multicenter, Open-label, Randomized, Phase III Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR) [NCT02811861]. Principal Investigator: Sandhya Srinivas, MD; Contact: Shermeen Poushnejad, (650) 724-7662; shermeen@stanford.edu.
- HEP0057: Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET): A Phase 2 Randomized Multicenter Trial to Compare Hepatic Progression-Free Survival Following Bland Embolization, Lipiodol Chemoembolization, and Drugeluting Bead Chemoembolization of Neuroendocrine Liver Metastases [NCT02724540]. Principal Investigator: Nishita Kothary, MD; Contact: Harris Naemi, (650) 736-6524; harrisn@stanford.edu.
- LUN0080-CCT5004: A Phase I Dose Escalation, Open-Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) [NCT02592577]. Principal Investigator: Joel Neal, MD; Contact: Jordan Preiss, (650) 723-1002; jpreiss2@stanford.edu.
- CCT5001: Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies [NCT03233854]. Principal Investigator: David Mikos, MD; Contact: Matthew Abramian, (650) 736-3351; abramian@stanford.edu.
- HEMMYL0028: Open-Label, Multicenter, Dose-Escalation/Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics, and Activity of BET Inhibitor RO6870810, Given as Mono- and Combination Therapy to Patients with Advanced Multiple Myeloma [NCT03068351]. Principal Investigator: Michaela Liedtke, MD; Contact: Uzma Ahmed, (650) 723-0670; uzma.ahmed@stanford.edu.
- HEMMPD0028: A Phase II, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Myeloid/Lymphoid Neoplasms With

FGFR1 Rearrangement [NCT03068351]. Principal Investigator: Jason Gotlib, MD; Contact: Justin Abuel, (650) 723-1367; jabuel@stanford.edu.

- HEMMPD0029: A Multicenter Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies [NCT02571036]. Principal Investigator: Jason Gotlib, MD; Contact: Justin Abuel, (650) 723-1367; jabuel@stanford.edu.
- PEDSBMT297: Use of T-all10 Cell Infusions Combined with Mismatched Related or Mismatched Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies [NCT03198234]. Principal Investigator: Rajni Agarwal-Hasmi, MD; Contact: Gopin Saini, (650) 725-9032; sainig@stanford.edu.
- COGAALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B- Acute Lymphoblastic Leukemia (B-ALL) [NCT02981628]. Principal Investigator: Sheri Spunt, MD; Contact: Chastity Woodlief, (650) 725-1662; cwoodlief@stanford.edu.
- SARCOMA0028: A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies [NCT02571036]. Principal Investigator: Kristen Ganjoo, MD; Contact: Maria Ahern, (650) 725-6413; mahern@stanford.edu.

Further information is available at cancer.stanford.edu/trials/.

Publications, Resources, Services, & Surveys

ANCO's 2017 *Annual Report* is now available online at www.anco-online.org/AR2017.pdf and was mailed to all ANCO physician members the last week in November.

ASCO's *Clinical Affairs Department* provides services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape.

Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/practice-guidelines/practice-support.

ASCO has issued two new guidelines—an update on platelet transfusion for people with cancer and an update on the use of larynx-preservation strategies in the treatment of laryngeal cancer.

Read the updates at www.asco.org/practice-guidelines/quality-guidelines/guidelines/supportive-care-and-treatment-related-issues#/10171 and www.asco.org/practice-guidelines/quality-guidelines/guidelines/head-and-neck-cancer#/10261, respectively.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Learn more and enroll at www.asco.org/practice-guidelines/practice-support/practicenet?et_cid=39764896&et_rid=933038345&linkid=Enroll+in+PracticeNET.

ASCO and *Innovative Oncology Business Solutions (IOBS)* have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer. ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA. ASCO is currently accepting practices for the fee-based program. For more information, please visit www.asco.org/practice-guidelines/practice-support/asco-consulting-services/asco-come-home.

The November 2017 issue of ASCO's *Journal of Oncology Practice (JOP)* is available online and features articles Role of Kindness in Cancer Care; End-of-Life Services Among Patients With Cancer: Evidence from Cancer Registry Records Linked With Commercial Health Insurance Claims; Choosing Wisely in Oncology: Are We Ready for Value-Based Care?; Discussing Health Care Expenses in the Oncology Clinic: Analysis of Cost Conversations in Outpatient Encounters; and, American Society of Clinical Oncology Statement on the Impact of Utilization Management Policies for Cancer Drug Therapies. Visit jop.ascopubs.org for more information.

NCCN has published and/or updated their *Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Evidence Blocks, Guidelines for Patients, Imaging Appropriate Use Criteria, and/or Radiation Therapy Compendium* for: breast cancer (V3.2017), cancer- and chemotherapy-induced anemia (V2.2018), cervical cancer (V1.2018), melanoma (V1.2018), multiple myeloma (V3.2018), non-small cell lung cancer (V1.2018), occult primary (V1.2018), vulvar cancer (V1.2018). Go to www.nccn.org for more information.

Individual Membership Dues for 2018

Membership renewal notices for 2018 were mailed to all members in late November, along with annual election ballots and the *2017 Annual Report*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse manager contact(s). Those not renewing their membership by June 30th will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you do not receive or misplaced your membership dues renewal notice.